Eye Care Products Recalled – Full FDA List and Steps

A major recall of over 3.1 million bottles of eye drops has been issued by K.C. Pharmaceuticals in March 2026, affecting multiple brands distributed nationwide through retailers including Walgreens, CVS, Kroger, and Rite Aid. The U.S. Food and Drug Administration has classified this as a Class II recall due to concerns about sterility assurance during manufacturing.

The affected products span several store brands and formulations commonly used for dry eye relief, lubrication, and redness treatment. Health authorities are advising consumers to check their medicine cabinets and return or discard any products matching the identified lot codes. While serious health consequences remain unlikely, the recall highlights ongoing quality control challenges in the over-the-counter ophthalmic market.

This recall adds to a series of eye drop safety alerts issued between 2023 and 2026, prompting consumers to verify whether their preferred brands are affected and understand the appropriate steps to take.

FDA Eye Drop Recall List

The FDA recall list identifies six distinct products affected by the March 2026 K.C. Pharmaceuticals recall. Each product is associated with multiple lot codes and expiration dates, spanning from April 2026 through October 2026. Retailers distributed these items under various store brand labels, making it essential for consumers to examine packaging carefully rather than relying solely on product name recognition.

Key Facts About the Recall

• 3.1 million bottles recalled across all affected products
• Class II recall classification by the FDA indicates temporary or reversible health consequences
• Products sold at major retailers nationwide including Walgreens, CVS, Kroger, and Rite Aid
• Primary concern involves lack of sterility assurance during manufacturing
• Lot codes expire between April 2026 and October 2026
• Largest single lot exceeded 1 million bottles distributed through Rite Aid, H-E-B, and Harris Teeter

Complete Product and Lot Code Reference

Which Eye Care Products Have Been Recalled Nationwide?

The March 2026 recall encompasses products distributed under numerous store brand labels across the retail landscape. The Leader brand appears across multiple product categories, including Dry Eye Relief, Artificial Tears, and Sterile Eye Drops Redness Lubricant. Other affected distributors include Geri-Care, TopCare Health, Good Sense, Good Neighbor Pharmacy, Best Choice, Kroger, Publix, Walgreens, CVS Health, Rugby, Discount Drug Mart, H-E-B, Foster & Thrive, Meijer, DG Health, Harris Teeter, Exchange Select, Equaline, and Code Red.

Health experts emphasize that consumers should verify lot numbers rather than relying solely on brand names or retailers, as the same product may appear under multiple labels. The FDA maintains an official recall database where individuals can cross-reference specific lot codes to determine whether their product falls within the affected batch.

Recall Classification and Health Implications

The FDA classified this recall as Class II, indicating that temporary or reversible health consequences are possible but serious outcomes remain unlikely. The underlying issue involves manufacturing conditions that may have compromised product sterility rather than contamination detected in finished products.

Previous eye drop recalls, including those issued in 2023, were associated with bacterial contamination including Pseudomonas aeruginosa, which led to infections, vision loss, and fatalities. The current recall does not appear to involve detected contamination but rather preventive measures based on sterility assurance deficiencies.

Are Popular Brands Like Refresh, Systane, and Blink Recalled?

Based on available FDA recall announcements and verified sources, popular over-the-counter eye drop brands including Refresh, Systane, and Blink do not appear on any current recall lists. Searches of official FDA databases and news reports from 2025 through early 2026 have not identified recall notices specifically naming these products.

Similarly, Maxitrol, a prescription steroid-antibiotic combination drop, does not appear in any over-the-counter artificial tears recall announcements. Patients using Maxitrol under a physician’s direction should continue their prescribed treatment unless otherwise advised by their healthcare provider.

Earlier Recalls Involving Similar Products

Prior recalls between 2023 and 2024 involved different manufacturers including Global Pharma (producing EzriCare and Delsam brands), Kilitch Healthcare (producing CVS, Target, and Walmart store brands), and Brassica Pharma. These recalls primarily cited bacterial contamination or unsanitary manufacturing conditions.

In May 2025, BRS Analytical Service recalled artificial tears distributed by AvKARE due to FDA inspection findings and unacceptable quality standards. The affected products carried expiration dates ranging from April 2025 through March 2027.

Eye Care Product Recalls in Australia

The eye drop recalls documented in available sources focus primarily on products distributed within the United States. No specific mentions of Australian distribution or separate Australian recall notices appear in the verified sources reviewed for this report.

Consumers in Australia seeking information about local recalls should consult the Therapeutic Goods Administration (TGA), Australia’s regulatory authority for therapeutic goods. The TGA maintains its own recall database and may issue region-specific alerts that differ from U.S. FDA announcements.

It is worth noting that some products affected by U.S. recalls may also be available through international online retailers serving Australian customers. In such cases, Australian consumers should exercise caution and verify product lot codes against both FDA and TGA announcements.

Timeline of Eye Drop Recall Events

Understanding the sequence of recall events helps contextualize the March 2026 K.C. Pharmaceuticals recall within broader industry quality control efforts. The following timeline summarizes key developments in eye drop safety alerts from 2023 through early 2026.

1. November 2023: The FDA issued warnings advising consumers not to purchase or use certain eye drop brands due to infection risks. Subsequent investigations identified bacterial contamination including Pseudomonas aeruginosa linked to serious health outcomes.
2. 2024: Multiple recalls involving Global Pharma, Kilitch Healthcare, and Brassica Pharma products. Retailers including CVS, Target, and Walmart removed affected products from shelves.
3. May 2025: BRS Analytical Service recalled artificial tears distributed by AvKARE due to FDA inspection issues and unacceptable quality standards. Approximately 1.8 million cartons were affected according to industry reports.
4. March 2026: K.C. Pharmaceuticals recalled over 3.1 million bottles of eye drops across six product lines. The FDA classified this as a Class II recall citing lack of sterility assurance.

What’s Known and What Remains Unclear

Transparency about the boundaries of available information serves consumers seeking accurate guidance. The following comparison outlines established facts alongside areas where uncertainty persists.

Understanding the Broader Context

The March 2026 recall occurs within a broader pattern of quality control challenges affecting the over-the-counter ophthalmic industry. Between 2023 and 2026, multiple manufacturers have faced FDA action due to contamination issues or sterility assurance deficiencies.

Store brands, sometimes called private label products, appear prominently in recent recalls. These products are manufactured by third-party pharmaceutical companies and sold under retailer house labels. The Leader brand, which appears across multiple affected product categories, exemplifies this distribution model where a single manufacturer’s issue can impact numerous retail chains simultaneously.

The FDA’s Class II classification indicates regulatory awareness that while the products may not meet quality standards, the probability of serious adverse health events remains low. This classification contrasts with Class I recalls, which involve situations where serious health consequences or death are reasonably probable.

Official Statements and Expert Guidance

The FDA has advised consumers who have purchased affected products to stop using them immediately and either return the products to the place of purchase or discard them according to local regulations. Consumers experiencing any unusual symptoms after using eye drops should consult their healthcare provider or an eye care professional.

The FDA warns consumers not to purchase or use certain eye drops from several major brands due to the risk of eye infection. Consumers should check the lot numbers on their products and compare them against the official recall list.

— U.S. Food and Drug Administration

Eye care professionals recommend that patients maintain awareness of recall announcements and regularly check product packaging, particularly for individuals who use over-the-counter eye drops frequently or have pre-existing eye conditions. Regular consultation with an optometrist or ophthalmologist can provide personalized guidance based on individual eye health needs.

Summary

The March 2026 recall by K.C. Pharmaceuticals affecting over 3.1 million bottles of eye drops represents a significant quality control action involving six distinct product lines distributed through major U.S. retailers. Products affected include Dry Eye Relief Eye Drops, Artificial Tears Sterile Lubricant Eye Drops, Eye Drops Advanced Relief, Sterile Eye Drops Redness Lubricant, Sterile Eye Drops A.C., and Sterile Eye Drops Soothing Tears. The FDA has classified this as a Class II recall, indicating temporary or reversible health risks are possible but serious consequences are unlikely.

Consumers using eye drops should verify their product lot codes against the official recall list. Popular brands including Refresh, Systane, Blink, and Maxitrol have not appeared in current recall announcements, though individuals should remain alert to future updates. Those in Australia should consult the TGA for region-specific guidance. For additional context on related health topics, see our guide on anatomy and health resources.

Frequently Asked Questions